PTM Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PTM Therapeutics is an early-stage biotech pioneering a novel approach to drug discovery by targeting Post-Translational Modifications (PTMs), which are protein alterations prevalent in disease states. The company has developed a proprietary 'Conditioned Target Discovery Platform' to generate therapeutic antibodies against these targets, with two initial programs focused on inflammatory bowel disease/ulcerative colitis and metastatic colon cancer. Operating as a private, pre-revenue entity, PTM aims to tap into a significant and underexplored area of biology to develop more specific and effective treatments.

Inflammatory Bowel DiseaseOncology

Technology Platform

Proprietary 'Conditioned Target Discovery Platform' that uses disease-relevant cellular states (e.g., cytokine-conditioned cells or tumor-stroma co-cultures) as immunogens to generate antibodies against disease-specific Post-Translational Modification (PTM) targets on the cell surface.

Opportunities

The company is targeting large, underserved markets in IBD and colorectal cancer with a novel mechanism focused on PTMs, which could offer superior specificity.

Success with initial programs could validate its platform, enabling expansion into numerous other chronic diseases and cancers with high unmet need.

Risk Factors

The core scientific approach of targeting PTMs with antibodies is novel and unproven, carrying high technical risk.

As a pre-revenue, private company, it faces significant financial risk and depends on future fundraising.

Its early-stage programs must survive the high attrition rate of drug development.

Competitive Landscape

PTM operates in highly competitive therapeutic areas (IBD, CRC) dominated by large pharma and biotech. Its niche focus on PTM-targeting antibodies is differentiating, but it faces indirect competition from all other modality approaches. If successful, it may attract rapid competitive entry from well-resourced players.

More companies in Biologics / Biosimilars →More companies in United States →